Immunohistochemical characterization of molecular classification of breast carcinoma and its relation with Ki-67

Karangadan, Shabnam; Patil, Anuradha G.; Andola, Sainath K

doi:10.4103/2278-0513.197876

Cited by 8 publications

(13 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Out of 65 cases of Triple negative, 3 were reported as Medullary carcinoma, 1 case was reported as Lymphoepithelioma-like carcinoma and rest other cases were IDC NST. All three cases of medullary carcinoma were of triple negative subtype which correlated with studies by Su et al [16], Engstrom et al [2] and Karangadan S et al [17]. Our findings are concordant with the study conducted by Gogoi G. et al [18] in Northeast India showing triple negative as the predominant molecular subtype (38.21%).…”

Section: Discussionsupporting

confidence: 92%

“…Our findings are concordant with the study conducted by Gogoi G. et al [18] in Northeast India showing triple negative as the predominant molecular subtype (38.21%). Similar results were found in the study conducted by Karangadan S et al [17], showing triple negative as the most common molecular subtype (40.00%) followed by luminal B (23.33%). In contrast western studies carried out by Ihemelandu CU et al [19] and Park S et al [20] documented that the most common molecular subtype in their study was Luminal A.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

A Study of Molecular Subtypes of Carcinoma Breast by Immunohistochemistry at Tertiary Care Center, Jaipur

Jindal

Priyanka

Solanki

2022

Asian Pac J Cancer Biol

View full text Add to dashboard Cite

Introduction: Breast cancer is one of the most common malignant tumors and one of the leading causes of cancer related death amongst females worldwide. The clinical significance of molecular classification of carcinoma breast remains to be established. Molecular subtyping using immunohistochemistry can provide additional prognostic and predictive information. Aim and objectives: To identify morphological variants of carcinoma breast and to determine various proportions of molecular subtypes of carcinoma breast by immunohistochemistry. Materials and Methods: A descriptive type of observational study was done at SMS Medical College, Jaipur. 65 Modified Radical Mastectomy specimens received in the department were included in the study. The surgical specimens were then evaluated histopathologically and immunohistochemically for ER, PR, HER2/neu, and Ki67 markers. Results: Out of 65 breast carcinoma cases the most common histological type encountered in our study was Invasive ductal carcinoma of no special type (NST) (83.09%) followed by medullary carcinoma (4.63%) and invasive lobular carcinoma (3.09%) and a single case each of tubular, cribriform, metaplastic, lymphoepithelioma like carcinoma, carcinoma with apocrine differentiation and oncocytic carcinoma. The cases were further classified into molecular subtypes using protein expression patterns in IHC. The proportion of tumors found were Luminal A (32.31%), Luminal B (18.46%), HER2/neu overexpressed (13.84%), and Triple-negative (35.39%). Conclusion: The most common molecular subtype found in our study was Triple negative. The use of IHC markers in the clinical setting could determine the prognosis and benefit the patients with targeted therapies.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 90%

A Study of Molecular Subtypes of Carcinoma Breast by Immunohistochemistry at Tertiary Care Center, Jaipur

Jindal

Priyanka

Solanki

2022

Asian Pac J Cancer Biol

View full text Add to dashboard Cite

show abstract

“…The maximum numbers of females in our study were perimenopausal (55.9%). Similar results were found by Karangadan S et al [10], Nabi MG. et al [12]. In the present study, all triple negative and HER2-rich subtype patients had a tumor size of > 2 cm compared to 78% of patients with luminal subtypes A and B.…”

Section: Discussionsupporting

confidence: 90%

“…"Proliferative index can also be measured by immunohistochemical detection of cellular proteins produced during the cell cycle, eg Ki-67. Carcinomas with high proliferation rates have a poorer prognosis but may respond better to chemotherapy" [10]. Thus, the current therapeutic approach for breast carcinoma consists of a combination of surgery, postoperative radiation, hormonal treatment, chemotherapy, and Trastuzumab.…”

Section: Introductionmentioning

confidence: 99%

Molecular Classification of Breast Carcinoma Based on the Prognostic Marker: A Clinico-pathological Correlation

Kumar

Singh

Chandra

et al. 2022

JAMMR

View full text Add to dashboard Cite

Background: Breast cancer (BC) has now surpassed lung cancer as the leading cause of global cancer incidence in 2020, with an estimated 2.3 million new cases, representing 11.7% of all cancer cases. It is a highly heterogeneous disease with a variety of morphologic and clinical manifestations which results in a range of responses to treatment. Recently, targeted therapies based on the genetic, hormonal, or immunohistochemical (IHC) subtypes of breast cancer have been used. Objective: The study was a prospective hospital-based observational study with a sample size of 150 cases. The study aimed to determine the distribution of various molecular subtypes of breast carcinoma and also correlate the expression status of ER, PR, Her2neu, and Ki 67 with the patient's age, tumor size, tumor type, histological grade, lymph node status, and TNM staging. Results: 96.7% of cases were invasive ductal carcinoma (NOS). Most of the grade 1 tumors (68.8%) were both ER and PR positive. Grade 2 tumors had almost equal distribution with 39.4% of patients being ER & PR positive and 43.7% being both ER & PR negative. Almost all grade 3 tumors (88.9%) were both ER and PR -negative. Conclusion: IHC markers are cost-effective and easily available worldwide even in resource-poor countries like India. A greater understanding of the molecular classification of breast carcinoma based on triple markers will help in the development of targeted therapies that will lead to increased efficacy, decreased toxicity, increased disease-free survival, and better selection of patients who will benefit from treatment.

show abstract

“…They detected a statistically significant relevance between BC subtypes and the patient's age, histological grade, and Ki-67 activity. Furthermore, they found a link between ER/PR expression and histological grade and Ki-67 activity (17).…”

Section: Discussionmentioning

confidence: 99%

Comparison of ER, PR, Ki67 and HER-2/neu Reactivity Pattern with Patients’ Age, Histologic Grade, Tumor Size and Lymph Node Status in Invasive Ductal Breast Cancer

2020

View full text Add to dashboard Cite

Background: Breast cancer is the most prevalent neoplasm diagnosed in Iranian women. Objectives: The current study was performed to measure the hormone receptor status and its possible connection with the patient’s age, tumor size, histological grade, and lymph node status and involvement in patients with invasive ductal breast cancer (IDBC) Methods: A total of 103 women with IDBC recently diagnosed at the Department of Pathology of Shohada-E-Tajrish Hospital were entered into this study. The mean age of the patients was 48.4 years, and 59.2% of cases were 50 years old or less. Results: Most lesions (78.6%) were more than 2 cm at their greatest dimension. Grade-II lesions were observed in a large number of patients and 59.8% of cases had lymph node involvement. Positive ER, PR, and HER-2/neu were detected in 59%, 57%, and 29% of patients, respectively. A significant correlation was found between patients’ age and histologic score, tumor dimension and both histologic score and nuclear grade, and, finally, between lymph node involvement and nuclear grade. Conclusions: According to previous studies, the evaluation of hormone receptor status in patients with breast cancer is strongly recommended. Here, by studying its possible connection with the patient’s age, tumor size, histological grade, and lymph node metastasis, we detected some biomarkers, which could be used as prognostic indices in these patients. These biomarkers could help us in the clinical management of patients with IDBC by providing the best therapeutic options.

show abstract

Immunohistochemical characterization of molecular classification of breast carcinoma and its relation with Ki-67

Cited by 8 publications

References 2 publications

A Study of Molecular Subtypes of Carcinoma Breast by Immunohistochemistry at Tertiary Care Center, Jaipur

A Study of Molecular Subtypes of Carcinoma Breast by Immunohistochemistry at Tertiary Care Center, Jaipur

Molecular Classification of Breast Carcinoma Based on the Prognostic Marker: A Clinico-pathological Correlation

Comparison of ER, PR, Ki67 and HER-2/neu Reactivity Pattern with Patients’ Age, Histologic Grade, Tumor Size and Lymph Node Status in Invasive Ductal Breast Cancer

Contact Info

Product

Resources

About